Archiv
Archiv anzeigen:
bis


Anticoagulant-Associated Heavy Menstrual Bleeding

David Green, MD, PhD reviewing Boonyawat K et al. Blood 2017 Nov 1

Management is guided by risk for thrombosis and severity of bleeding.


Familial Thrombophilia as a Warning Flag for Pregnancy-Associated VTE

Eleanor Bimla Schwarz, MD, MS reviewing Croles FN et al. BMJ 2017 Oct 26

Most, but not all, familial thrombophilias warrant prophylactic anticoagulation during pregnancy and postpartum.


Nivolumab for Chemotherapy-Refractory Gastric Cancer

David H. Ilson, MD, PhD reviewing Kang YK et al. Lancet 2017 Oct 6

Survival was significantly prolonged with nivolumab versus placebo.


Neurologic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy for Cancer

John C. Probasco, MD reviewing Kao JC et al. JAMA Neurol 2017 Oct 01, Suzuki S et al. Neurology 2017 Sep 12

Two studies report a spectrum of subacute neurological complications after initiating treatment for various solid tumors.


Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Oudard S et al. J Clin Oncol 2017 Oct 1, Eisenberger M et al. J Clin Oncol 2017 Oct 1

Survival was similar with cabazitaxel versus docetaxel and with a lower versus higher dose of cabazitaxel.


Safety of Direct-Acting Oral Anticoagulants vs. Warfarin for Venous Thromboembolism

Paul S. Mueller, MD, MPH, FACP reviewing Jun M et al. BMJ 2017 Oct 17

Risks for major bleeding and all-cause death within 90 days were similar.


Do Transfusions from Female Donors Increase Mortality in Male Recipients?

David Green, MD, PhD reviewing Caram-Deelder C et al. JAMA 2017 Oct 17, Cable RG and Edgren G. JAMA 2017 Oct 17

Deaths were more frequent in male patients who received red cells from an ever-pregnant female donor than from a male donor.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.


Obinutuzumab vs. Rituximab for Follicular Lymphoma

Michael E. Williams, MD, ScM reviewing Marcus R et al. N Engl J Med 2017 Oct 5, Armitage JO and Longo DL. N Engl J Med 2017 Oct 5

Adding obinutuzumab to chemotherapy produced longer responses in previously untreated patients, but also a higher rate of severe adverse events.


Brentuximab Vedotin for Anaplastic Large-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Pro B et al. Blood 2017 Oct 3

Durable remissions were induced in patients with relapsed or refractory disease.


Archiv
Seite von 60
Editorial Member Board Empfehlungen

Prof. Dr. med. Beat Thürlimann

Brustzentrum St. Gallen

Liebe Kolleginnen und Kollegen!

Auch die neue «Journal Watch»-Serie von ausgewählten Publikationen gibt Ihnen die Möglichkeit, sich rasch und effizient über wichtige Neuigkeiten zu informieren. Ich habe mich bei der Auswahl auf praxisrelevante Informationen konzentriert: Therapieoptionen und Resistenzmechanismen bei der grossen Gruppe der KRAS-mutierten NSCLC bleiben eine grosse Herausforderung, sowohl wissenschaftlich wie auch klinisch. Das Prostatakarzinom wird ebenso wie das Mammakarzinom nach molekularen Subtypen kategorisiert, in der Absicht, prognostische Gruppen zur Primärbehandlung besser abgrenzen zu können, und um molekulare «targets» zu finden, welche auch systemtherapeutisch angegangen werden können. Im Weiteren gibt es bei der Metastasierung des Prostatakarzinoms auch eine Reihe von neuen Therapiemöglichkeiten mit endokriner Therapie und Chemotherapie. Es geht dabei um den optimalen Gebrauch der neuen Therapien im Verlauf der Krankheit. Zwei Beiträge finden Sie zum onkologischen Dauerbrenner des Antikoagulanzieneinsatzes bei Tumorerkrankungen – eine Reise zwischen Skylla und Charybdis. Ein weiteres Dauerthema ist die Deeskalation bei der heutigen Tumortherapie. Zwei Beispiele sind ausgewählt worden: eine Untersuchung zur Stammzelltransplantation und die Problematik, eine erfolgreich eingesetzte Substanz im Verlauf auch wieder zu stoppen. Schliesslich wird die neue, sehr wirksame Therapie in Form von Pembrolizumab beim refraktären Hodgkin-Lymphom gezeigt: ein entscheidender Fortschritt für die Betroffenen.

Kommentar weiterlesen

Direct Oral Anticoagulants for Heparin-Induced Thrombocytopenia

David Green, MD, PhD reviewing Warkentin TE et al. Blood 2017 Jun 23

A systematic literature review finds DOACs safe and effective for HIT.


Combination Therapy for Metastatic Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing James ND et al. N Engl J Med 2017 Jun 3, Fizazi K et al. N Engl J Med 2017 Jun 4

Adding abiraterone and prednisone to androgen-deprivation therapy significantly improved survival.


Stem-Cell Transplantation Ineffective for Double-Hit Lymphoma

Michael E. Williams, MD, ScM reviewing Landsburg DJ et al. J Clin Oncol 2017 May 5

Consolidative autologous SCT did not improve survival for patients in first remission after induction chemoimmunotherapy.


Prostate Cancer Molecular Subtypes: How Predictive or Prognostic?

Robert Dreicer, MD, MS, FACP, FASCO reviewing Zhao SG et al. JAMA Oncol 2017 May 11, Abida W and Scher HI. JAMA Oncol 2017 May 11

Patients with luminal B tumors respond better to postoperative androgen-deprivation therapy than do those with non–luminal B tumors.


Selumetinib for KRAS-Mutated Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Jänne PA et al. JAMA 2017 May 9

The MEK inhibitor selumetinib does not appear to improve survival, contrary to prior findings.


Intracranial Hemorrhage in Anticoagulated Glioma Patients

David Green, MD, PhD reviewing Mantia C et al. Blood 2017 May 3

Anticoagulation with enoxaparin significantly increased risk for major intracranial hemorrhage in patients with glioma.


Stopping Eculizumab in Patients with Atypical Hemolytic Uremic Syndrome

David Green, MD, PhD reviewing Merrill SA et al. Blood 2017 May 1

Eculizumab can be discontinued despite continued complement activation.


Pembrolizumab for Relapsed or Refractory Classical Hodgkin Lymphoma

Michael E. Williams, MD, ScM reviewing Chen R et al. J Clin Oncol 2017 Apr 25

Two thirds of patients responded to treatment with the immune checkpoint inhibitor.


Management of Localized Prostate Cancer: Data at Last

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hamdy FC et al. N Engl J Med 2016 Sep 14, D'Amico AV. N Engl J Med 2016 Sep 14

Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.


Hereditary Thrombophilia and Risk for Pregnancy-Associated Venous Thromboembolism

David Green, MD, PhD reviewing Gerhardt A et al. Blood 2016 Sep 9

Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.